BioSnap is a technology company.
BioSnap has raised $20K across 1 funding round.
BioSnap has raised $20K in total across 1 funding round.
BioSnap refers to multiple entities in the biotech and automation space, with the most prominent being a technology company focused on AI-driven process automation in sterile environments, such as cleanrooms and pharmaceuticals.[1][4][6] It develops devices and integrated AI solutions to enhance clean room sampling, sterility testing, and automation, serving industries like research services, biopharma, and manufacturing.[1][4] This addresses challenges in contamination control and efficiency in sterile settings, with growth evidenced by specialized hardware like the BioSnap Telecentric Analyzer for high-precision bioassays (e.g., viral plaque assays, colony counting).[3] Other variants include a sustainable packaging project using biodegradable bioplastics with Easysnap technology for unit-dose sachets[2][8] and an AI-powered digital pathology platform for remote slide analysis, which raised ₹8 crore in seed funding.[5]
BioSnap's core technology company emerged to tackle inefficiencies in sterile process automation, leveraging AI integration for cleanroom devices, though specific founding year and founders are not detailed in available sources.[1][4][6] The Brazilian entity (biosnap.com.br) positions itself as an innovator in sterile environments, likely building on global biotech needs post-pandemic.[6] Parallel projects like the EU-funded BIOSNAP initiative originated from Proplast and Easysnap Machinery to extend patented snap-open technology into eco-friendly PHA/PLA bioplastic packaging, aiming for sustainable unit-dose solutions compliant with EU plastic reduction directives.[2][8] In imaging, the BioSnap Telecentric Analyzer from ImmunoSpot evolved for versatile bioassays in petri dishes and well plates.[3] The Indian BioSnap spun out to advance AI digital pathology, securing early seed investment for remote diagnostics.[5] Pivotal traction includes specialized hardware adoption and funding for pathology AI.
BioSnap rides the wave of AI-biotech convergence in sterile manufacturing and diagnostics, fueled by post-2020 demand for contamination-free automation in pharma and cleanrooms amid regulatory pressures like EU plastic bans.[1][2][6][8] Timing aligns with biopharma's shift to high-throughput assays and sustainable packaging, where market forces favor AI tools reducing manual errors in viral testing and pathology—critical for vaccine development and personalized medicine.[3][5] It influences the ecosystem by enabling faster R&D cycles, from microbial sterility checks to eco-packaging, supporting broader trends in green biotech and telehealth amid labor shortages in sterile ops.
BioSnap is poised to expand AI-sterile tech amid rising cleanroom demands, potentially integrating pathology AI with automation hardware for end-to-end biopharma workflows.[1][3][5][6] Trends like EU sustainability mandates and AI assay acceleration will propel growth, with the packaging arm scaling biodegradable innovations globally.[2][8] Its influence may evolve toward full-stack sterile AI platforms, consolidating fragmented tools—watch for partnerships in high-throughput biomanufacturing to dominate precision biotech. This positions BioSnap as a key enabler in resilient, green supply chains, echoing its mission to transform sterile processes.[1]
BioSnap has raised $20K in total across 1 funding round.
BioSnap's investors include Parallel18.
BioSnap has raised $20K across 1 funding round. Most recently, it raised $20K Seed in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2024 | $20K Seed | Parallel18 |